Cremimycin is a macrolide antibiotic that exhibits antibacterial properties, primarily effective against a range of Gram-positive bacteria. It is derived from natural sources, specifically from certain strains of Streptomyces, which are known for their ability to produce various bioactive compounds. The chemical structure of Cremimycin features a large lactone ring, characteristic of macrolides, which is essential for its mechanism of action. This antibiotic works by inhibiting bacterial protein synthesis, thereby preventing the growth and reproduction of susceptible bacteria. Cremimycin has been studied for its potential therapeutic applications, particularly in treating infections caused by resistant bacterial strains. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile. As with many antibiotics, the development of resistance is a significant concern, necessitating careful use and ongoing research to optimize its clinical applications. Overall, Cremimycin represents a valuable addition to the arsenal of antibiotics, particularly in the context of increasing antibiotic resistance.

Cremimycin (antibiotic)

182285-29-6: Cremimycin is a macrolide antibiotic that exhibits antibacterial properties, primarily effective against a range of Gram-positive bacteria. It is derived from natural sources, specifically from certain strains of Streptomyces, which are known for their ability to produce various bioactive compounds. The chemical structure of Cremimycin features a large lactone ring, characteristic of macrolides, which is essential for its mechanism of action. This antibiotic works by inhibiting bacterial protein synthesis, thereby preventing the growth and reproduction of susceptible bacteria. Cremimycin has been studied for its potential therapeutic applications, particularly in treating infections caused by resistant bacterial strains. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for determining its efficacy and safety profile. As with many antibiotics, the development of resistance is a significant concern, necessitating careful use and ongoing research to optimize its clinical applications. Overall, Cremimycin represents a valuable addition to the arsenal of antibiotics, particularly in the context of increasing antibiotic resistance.

<p>Cremimycin exhibits activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 0.2-0.39 μg/mL. Additionally, Cremimycin demonstrates cytotoxic effects on mouse tumor cell lines P388, L1210, IMC, S180, B16, and SS3 in vitro.</p>

CAS 182285-29-6

Cremimycin (antibiotic)

Cremimycin

Ref: TM-TN10012